The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism

Table 2

The effects of Nrf2 activators in rodent models of NAFLD or NASH.

Nrf2 activator	Species	Administration route	Reported effect	Reference
CDDO-Im	Mouse	Oral	Prevented HFD-induced increases in body weight, adipose mass, and hepatic lipid accumulation	[24]
CDDO-Me	Mouse	Oral	Reduced hepatic lipid accumulation, proinflammatory cytokine expression, and lipogenic gene expression in mice fed HFD	[26]
Sulforaphane	Mouse	Intraperitoneal	Attenuated hepatic fibrosis induced by bile duct ligation	[27]
Sulforaphane	Mouse	Oral	Suppressed oxidative stress and hepatic fibrosis induced by MCD diet	[28]
Oltipraz, NK-252	Rat	Oral	Attenuated hepatic fibrosis induced by CDAA diet	[29]

CDAA, choline-deficient L-amino acid-defined diet; CDDO-Im, 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole; CDDO-Me, 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]methyl; HFD, high-fat diet; MCD, methionine- and choline-deficient diet.